...
clnn-img

Clene Inc., Common Stock

CLNN

NAQ

$4.7

-$0.25

(-5.05%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$39.50M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
47.31K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.41
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$3.82 L
$12 H
$4.7

About Clene Inc., Common Stock

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameCLNNSectorS&P500
1-Week Return-1.05%-3.72%-0.05%
1-Month Return6.82%-1.85%2.75%
3-Month Return-15.92%-11.4%7.4%
6-Month Return-36.49%-4.41%10.47%
1-Year Return-53%4.13%27.57%
3-Year Return-95.46%0.3%29.56%
5-Year Return-97.74%36.62%89.3%
10-Year Return234900%106.81%206.09%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue-206.00K723.00K473.00K654.00K[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":28.49,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":65.42,"profit":true},{"date":"2023-12-31","value":90.46,"profit":true}]
Cost of Revenue900.00K65.00K289.00K26.00K121.00K[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":7.22,"profit":true},{"date":"2021-12-31","value":32.11,"profit":true},{"date":"2022-12-31","value":2.89,"profit":true},{"date":"2023-12-31","value":13.44,"profit":true}]
Gross Profit(900.00K)141.00K434.00K447.00K533.00K[{"date":"2019-12-31","value":-168.86,"profit":false},{"date":"2020-12-31","value":26.45,"profit":true},{"date":"2021-12-31","value":81.43,"profit":true},{"date":"2022-12-31","value":83.86,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Margin-68.45%60.03%94.50%81.50%[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":72.43,"profit":true},{"date":"2021-12-31","value":63.52,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":86.24,"profit":true}]
Operating Expenses15.73M17.14M45.71M45.78M41.07M[{"date":"2019-12-31","value":34.37,"profit":true},{"date":"2020-12-31","value":37.45,"profit":true},{"date":"2021-12-31","value":99.85,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":89.72,"profit":true}]
Operating Income(16.33M)(17.00M)(45.28M)(45.33M)(40.54M)[{"date":"2019-12-31","value":-1633200000,"profit":false},{"date":"2020-12-31","value":-1700400000,"profit":false},{"date":"2021-12-31","value":-4527600000,"profit":false},{"date":"2022-12-31","value":-4533000000,"profit":false},{"date":"2023-12-31","value":-4054000000,"profit":false}]
Total Non-Operating Income/Expense89.00K393.00K35.76M14.42M(13.52M)[{"date":"2019-12-31","value":0.25,"profit":true},{"date":"2020-12-31","value":1.1,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":40.33,"profit":true},{"date":"2023-12-31","value":-37.81,"profit":false}]
Pre-Tax Income(16.16M)(18.87M)(10.17M)(29.92M)(49.50M)[{"date":"2019-12-31","value":-1615500000,"profit":false},{"date":"2020-12-31","value":-1887100000,"profit":false},{"date":"2021-12-31","value":-1016800000,"profit":false},{"date":"2022-12-31","value":-2991800000,"profit":false},{"date":"2023-12-31","value":-4950400000,"profit":false}]
Income Taxes115.00K406.00K(428.00K)(14.64M)1.54M[{"date":"2019-12-31","value":7.48,"profit":true},{"date":"2020-12-31","value":26.41,"profit":true},{"date":"2021-12-31","value":-27.84,"profit":false},{"date":"2022-12-31","value":-952.37,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Income After Taxes(16.27M)(19.28M)(9.74M)(15.28M)(51.04M)[{"date":"2019-12-31","value":-1627000000,"profit":false},{"date":"2020-12-31","value":-1927700000,"profit":false},{"date":"2021-12-31","value":-974000000,"profit":false},{"date":"2022-12-31","value":-1527900000,"profit":false},{"date":"2023-12-31","value":-5104110500,"profit":false}]
Income From Continuous Operations(16.16M)(19.28M)(9.74M)(29.92M)(40.38M)[{"date":"2019-12-31","value":-1615500000,"profit":false},{"date":"2020-12-31","value":-1927700000,"profit":false},{"date":"2021-12-31","value":-974000000,"profit":false},{"date":"2022-12-31","value":-2991800000,"profit":false},{"date":"2023-12-31","value":-4038500000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(16.27M)(19.28M)(9.74M)(15.28M)(49.50M)[{"date":"2019-12-31","value":-1627000000,"profit":false},{"date":"2020-12-31","value":-1927700000,"profit":false},{"date":"2021-12-31","value":-974000000,"profit":false},{"date":"2022-12-31","value":-1527900000,"profit":false},{"date":"2023-12-31","value":-4950400000,"profit":false}]
EPS (Diluted)(0.20)(0.23)(0.39)(0.46)(0.52)[{"date":"2019-12-31","value":-19.59,"profit":false},{"date":"2020-12-31","value":-23,"profit":false},{"date":"2021-12-31","value":-39,"profit":false},{"date":"2022-12-31","value":-46,"profit":false},{"date":"2023-12-31","value":-52,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

CLNN
Cash Ratio 0.61
Current Ratio 0.83
Quick Ratio 0.82

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

CLNN
ROA (LTM) -41.71%
ROE (LTM) -289.66%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

CLNN
Debt Ratio Lower is generally better. Negative is bad. 1.13
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. -0.13

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

CLNN
Trailing PE NM
Forward PE NM
P/S (TTM) 89.37
P/B 7.83
Price/FCF NM
EV/R 113.39
EV/Ebitda NM

FAQs

What is Clene Inc. share price today?

Clene Inc. (CLNN) share price today is $4.7

Can Indians buy Clene Inc. shares?

Yes, Indians can buy shares of Clene Inc. (CLNN) on Vested. To buy Clene Inc. from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CLNN stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Clene Inc. be purchased?

Yes, you can purchase fractional shares of Clene Inc. (CLNN) via the Vested app. You can start investing in Clene Inc. (CLNN) with a minimum investment of $1.

How to invest in Clene Inc. shares from India?

You can invest in shares of Clene Inc. (CLNN) via Vested in three simple steps:

  • Click on Sign Up or Invest in CLNN stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Clene Inc. shares
What is Clene Inc. 52-week high and low stock price?

The 52-week high price of Clene Inc. (CLNN) is $12. The 52-week low price of Clene Inc. (CLNN) is $3.82.

What is Clene Inc. price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Clene Inc. (CLNN) is

What is Clene Inc. price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Clene Inc. (CLNN) is 7.83

What is Clene Inc. dividend yield?

The dividend yield of Clene Inc. (CLNN) is 0.00%

What is the Market Cap of Clene Inc.?

The market capitalization of Clene Inc. (CLNN) is $39.50M

What is Clene Inc.’s stock symbol?

The stock symbol (or ticker) of Clene Inc. is CLNN

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top